NewsSOS
Moderna shares soared Wednesday after the company reported promising results for its cancer vaccine program, according to CNBC's Jim Cramer, who included both names on his midweek market watchlist.
Target, he said, may be a victim of profit-taking. The Moderna rally follows a readout Cramer described as promising.
No trial phase, enrolled patient count, primary endpoint, or comparison arm was included in his summary.
Each of those details shapes whether a clinical result translates to a durable move: a headline efficacy signal can lift shares quickly, then give way once the full data set reaches investors.
Keep reading